TikTok - Make Your Day

Ajude a salvar a vida de #NatáliaCostaPimenta, dirigente nacional do PCO e vice-presidente do Ibraspal, que está internada numa UTI em batalha contra #Câncer na medula óssea e no sangue. Ela está precisando do caríssimo remédio #Revumenib -

www.tiktok.com/@izadoradias... -
Via Izadora Dias -

👇🏽 Trial finding that led to approval:

Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation.
📈 Led to FDA approval (2025) for R/R NPM1m AML.
#AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…

Assine o Abaixo-assinado Ajude a salvar a vida da companheira Natália Pimenta

Ajude a salvar a vida de #NatáliaCostaPimenta, dirigente nacional do PCO e vice-presidente do Ibraspal, que está internada numa UTI em batalha contra #Câncer na medula óssea e no sangue. Ela está precisando do caríssimo remédio #Revumenib

c.org/4FnfLC5M4D via @change_br -

Menin Inhibitor Revumenib Yields Clinically Meaningful Responses in R/R NPM1-Mutated AML | ASH Clinical News | American Society of Hematology

Among patients with R/R NPM1-mutated #AcuteMyeloidLeukemia #AML, treatment with #revumenib yielded clinically meaningful responses , including a 23.4% CR+CRh rate and a 46.9% ORR, with several patients able to proceed to #transplant following treatment: ow.ly/I4b150WELeJ
#HemeSky #HemeOnc

Menin Inhibitors: Transforming Hematologic Oncology for the Next Decade An in-depth analysis of the menin inhibitors market reveals significant growth potential, driven by innovations in hematologic oncology and targeted therapies.

Menin Inhibitors: Transforming Hematologic Oncology for the Next Decade #United_States #Las_Vegas #Revumenib #Hematologic_Oncology #Menin_Inhibitors

Chris De Savi: FDA Novel Drug approvals in 2024 - OncoDaily Chris De Savi: FDA Novel Drug approvals in 2024 / Acoramidis, acute leukemia, arrhythmia management, Biliary tract cancer, cancer, Cancer Cell, cell growth,

FDA Novel Drug approvals in 2024 - Chris De Savi
@fda.gov

oncodaily.com/blog/215120

#Acoramidis #AcuteLeukemia #ArrhythmiaManagement #BiliaryTractCancer #Cancer #CancerCell #CellGrowth #DrugDiscovery #FDA #GeneticDisorders #Landiolol #Medicine #OncoDaily #Oncology #Revumenib #SVTtherapies

2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA:

1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib

#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm

Revolutionary FDA-Approved Drug for Acute Leukemia Unveiled at Florida Cancer Specialists The FDA has approved revumenib, a groundbreaking drug for acute leukemia, marking a significant advancement in cancer treatment. This therapy, first administered in Florida, is now accessible to patients nationwide.

Revolutionary FDA-Approved Drug for Acute Leukemia Unveiled at Florida Cancer Specialists #United_States #FDA_Approval #Revumenib #Cancer_Research #Sarasota,_Florida

FDA approves revumenib for relapsed or refractory acute leukemia On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.

Important approval in a difficult to treat cohort leukemia #revumenib, a menin inhibitor, for #relapsedAML with #KMT2Atranslocation in adult and pediatric patients 1 year and older.

www.fda.gov/drugs/resour...